Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 9/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.56 |
| ▸ | SIRT6 | Q8N6T7 | 2/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5744480 | 0.82 | SIRT6 (0.60) | MAPTALDH1A1SIRT6POLBLMNA | |
| SCHEMBL374834 | 0.81 | SIRT6 (0.68) | MAPTALDH1A1SIRT6POLBLMNA | |
| SCHEMBL1045279 | 0.80 | SIRT6 (0.62) | MAPTALDH1A1SIRT6POLBLMNA | |
| SCHEMBL1989595 | 0.79 | SIRT6 (0.64) | MAPTALDH1A1SIRT6POLBLMNA | |
| SCHEMBL4252494 | 0.79 | SIRT6 (0.64) | MAPTALDH1A1SIRT6POLBLMNA | |
| SCHEMBL6992319 | 0.79 | SIRT6 (0.64) | MAPTALDH1A1SIRT6POLBLMNA | |
| SCHEMBL4248037 | 0.77 | SIRT6 (0.62) | MAPTALDH1A1SIRT6POLBLMNA | |
| SCHEMBL15271381 | 0.77 | SIRT6 (0.81) | MAPTALDH1A1SIRT6POLBLMNA | |
| SCHEMBL6151230 | 0.77 | SIRT6 (0.81) | MAPTALDH1A1SIRT6POLBLMNA | |
| SCHEMBL28879244 | 0.76 | SIRT6 (0.54) | MAPTALDH1A1SIRT6POLBLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7442698-B2 | Substituted heterocyclic compounds and methods of use | AMGEN INC. (US) | 2008-10-28 | — | — | US | disclosed |
| US-20050107374-A1 | Substituted heterocyclic compounds and methods of use | AMGEN INC. | 2005-05-19 | — | — | US | disclosed |
| US-20050026914-A1 | Substituted heterocyclic compounds and methods of use | AMGEN INC. | 2005-02-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050026914-A1 | Substituted heterocyclic compounds and methods of use | NFATC1, ICOS, BET1 | MAPT 1512/4885ALDH1A1 370/4885SIRT6 2716/4885 |
| US-20050107374-A1 | Substituted heterocyclic compounds and methods of use | ICOS, CD4, HLA-DRB1 | MAPT 333/4885ALDH1A1 1063/4885SIRT6 3760/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.